What Fueled The Previous Growth In The Asthma Drugs Market?
The asthma drugs market has seen considerable growth due to a variety of factors.
•The market for asthma medications has seen significant expansion in the past few years. Its growth is projected to continue, increasing from $23.96 billion in 2024 to $25.17 billion in 2025 with a compound annual growth rate (CAGR) of 5.0%.
There are numerous causes for this growth in the historical period, including environmental conditions, a rise in respiratory disorders, changes in lifestyle, and developments in healthcare infrastructure.
What Is The Expected Growth In The Asthma Drugs Market Size?
The asthma drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market for asthma medications is forecasted to experience robust expansion in the upcoming years, reaching a value of $31.98 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 6.2%.
This rising trend during the prediction period can be linked to escalating levels of air pollution, a growing elderly population, heightening awareness of healthcare, a shift towards personalized medicine, and innovative strides in biopharmaceuticals. Small molecule therapies, home-centric asthma treatment, biomarker-reliant therapy, advanced treatments for severe asthma, and cooperative efforts for asthma study are key trends expected to shape the market throughout the forecast period.
What Main Forces Are Fueling Expansion In The Asthma Drugs Market?
The rising prevalence of asthmatic conditions is projected to boost the development of the asthma drug market. Asthma, a chronic disease, leads to inflammation and constriction of the breathing passages, impairing the air flow from the nose and mouth to the lungs. With the escalating number of asthma incidents, the discovery of novel asthma drugs aimed at treating these conditions has escalated. For example, in April 2024, Asthma + Lung UK, a charity based in England, supporting individuals with lung-related ailments, reported that in 2021, 1,146 asthma-related fatalities were recorded in England. This number increased to 1,236 in 2022, indicating a worrying increase in deaths related to this condition through the year.
What Are The Primary Segments In The Global Asthma Drugs Market?
The asthma drugs market covered in this report is segmented –
1) By Type Of Asthma: Allergic, Non-Allergic
2) By Asthma Trigger Type: Adult-Onset Asthma, Child-Onset Asthma, Cough-Induced Asthma, Exercise-Induced Asthma, Occupational Asthma, Nocturnal Asthma, Steroid-Resistant Asthma
3) By Therapy: Preventive, Curative
4) By Drug Class: Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs
5) By End-User: Asthma Patients, COPD Patients
Subsegments:
1) By Allergic: Inhaled Corticosteroids (ICS), Leukotriene Receptor Antagonists (LTRAs), Monoclonal Antibodies
2) By Non-Allergic: Short-Acting Beta Agonists (SABAs), Long-Acting Beta Agonists (LABAs), Oral Corticosteroids
Pre-Book The Asthma Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Asthma Drugs Market?
Leading corporations in the asthma drugs market are emphasizing on modern developments like fixed-dose combination (FDC) drugs to improve treatment efficiency and patient compliance. A fixed-dose combination (FDC) drug is a pharmaceutical that combines two or more active components in a single dosage format, such as a pill, capsule, or inhaler. For example, Glenmark Pharmaceuticals, a firm based in India, introduced Indamet, a fixed-dose combination (FDC) drug in India for uncontrolled asthma patients in June 2022. This cutting-edge treatment merges Indacaterol, a long-acting beta-agonist, with Mometasone Furoate, an inhaled corticosteroid, and is available in several potencies, including 150 mcg of Indacaterol with Mometasone at 80 mcg, 160 mcg, and 320 mcg. Indamet, which is intended for daily use, targets adults and teenagers aged 12 years and up.
Who Are the Key Players in the Asthma Drugs Market?
Major companies operating in the asthma drugs market include:
• Pfizer Inc.
• Roche Holding AG
• Merck & Co. Inc.
• Bayer AG
• Sanofi S.A.
• AstraZeneca PLC.
• GlaxoSmithKline PLC.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Novartis International AG
• Mylan N.V.
• Cipla Limited
• Chiesi Farmaceutici S.p.A.
• Sun Pharmaceutical Industries Limited
• Hikma Pharmaceuticals
• Mundipharma International Limited
• Lupin Limited
• Glenmark Pharmaceuticals Limited
• Hetero Drugs Limited
• Alembic Pharmaceuticals Limited
• Sunovion Pharmaceuticals Inc.
• Amphastar Pharmaceuticals Inc.
• Beximco Pharmaceuticals Ltd
• Innoviva Inc.
• Vectura Group
• Circassia Group PLC
• Pulmatrix Inc.
• Atopix Therapeutics Limited
What Is The Most Dominant Region In The Asthma Drugs Market?
North America was the largest region in the asthma drugs market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
